

U.S.S.N.: 09/345,712

Filed: June 30, 1999

AMENDMENT AND RESPONSE TO OFFICE ACTION

Co
LA keratosis, and actinic keratosis comprising administering to the individual in need of treatment thereof an angiogenesis inhibitor in an amount effective to inhibit angiogenesis.

10. (twice amended) A method to treat the symptoms associated with elevated basic fibroblast growth factor in a disorder selected from the group consisting of angiosarcoma, hemangioendothelioma, [basal cell carcinoma, squamous cell carcinoma,] malignant melanoma and Kaposi's sarcoma[, and psoriasis], comprising administering to the individual in need of treatment an effective amount of a curcuminoid to inhibit angiogenesis [of a curcuminoid].

11. (amended) The method of claim 10 wherein the [angiogenesis inhibitor] curcuminoid is curcumin.

12. (amended) The method of claim 10 wherein the [angiogenesis inhibitor] curcuminoid is demethoxycurcumin.

Please cancel claims 13-16.

Sub
e 3 17. (amended) A method for inhibiting skin disorders selected from the group consisting of lymphangiogenesis, hemangioma of childhood, Sturge-Weber syndrome, verruca vulgaris, neurofibromatosis, tuberous sclerosis, pyogenic granulomas, recessive dystrophic epidermolysis bullosa, venous ulcers, [acne,] rosacea, eczema, molluscum contagiosum, seborrheic keratosis, and actinic keratosis comprising administering to the individual in need of treatment thereof an angiogenesis inhibitor in an amount effective to inhibit angiogenesis, wherein the angiogenesis inhibitor is selected from the group consisting of

tetracyclines inhibiting collagenase,

~~endostatin,~~